Flag of the European Union EU Clinical Trials Register Help

Clinical trials for McDonald criteria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    274 result(s) found for: McDonald criteria. Displaying page 4 of 14.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-003100-30 Sponsor Protocol Number: EFC13429 Start Date*: 2017-04-04
    Sponsor Name:Genzyme Corporation
    Full Title: A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclero...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) NO (Completed) GR (Completed) PT (Completed) NL (Prematurely Ended) BE (Prematurely Ended) BG (Temporarily Halted) Outside EU/EEA FR (Ongoing) PL (Completed) AT (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001290-14 Sponsor Protocol Number: EMR200136_583 Start Date*: 2014-10-24
    Sponsor Name:MERCK ROMANIA SRL
    Full Title: Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania using Electronic Device RebiSmart™
    Medical condition: Clinical isolated syndrome and relapse multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-000503-15 Sponsor Protocol Number: NEMESI-MS Start Date*: 2007-02-19
    Sponsor Name:AZ. OSPEDALIERA GARIBALDI, S.LUIGI CURRO , ASCOLI TOMASELLI
    Full Title: Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of mem...
    Medical condition: patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001281-13 Sponsor Protocol Number: KS-2004-06-SET Start Date*: 2005-11-15
    Sponsor Name:DSC Services, s.r.o.
    Full Title: Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET Study)
    Medical condition: Clinically isolated syndrome suspected from demyelinating event (no better explanation for present symptoms)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003127-38 Sponsor Protocol Number: NL71001.029.19 Start Date*: 2020-04-09
    Sponsor Name:VUmc Neurology Department
    Full Title: Efficacy of add-on high dose simvastatin on markers for disease progression in MS patients treated with ocrelizumab and natalizumab (SIMSON), a phase II clinical trial.
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004318-42 Sponsor Protocol Number: perfusie_pharma Start Date*: 2006-12-12
    Sponsor Name:Department of Neurology UMCG
    Full Title: Influence on brain perfusion and metabolism through pharmacologic agents
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005751-18 Sponsor Protocol Number: QS001 Start Date*: 2006-09-07
    Sponsor Name:UCL Biomedicine R&D Unit
    Full Title: A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies ...
    Medical condition: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system of unknown aetiology. It is the commonest cause of disability in young adults. The prevalence in the U...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002959-34 Sponsor Protocol Number: RETRAP Start Date*: 2013-03-11
    Sponsor Name:Sønderjylland Hospital, department of neurology
    Full Title: RETRAP - A double blind, randomized, placebo controlled study of the effect of the combination of resistance training and prolonged release fampridine on muscle strength in the lower extremities, w...
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004852 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008554-23 Sponsor Protocol Number: AIR Start Date*: 2009-12-29
    Sponsor Name:The Multiple Sclerosis Research Group, Department of Clinical Neuroscience
    Full Title: Neutralizing Antibodies to Interferon beta in patients treated with Rebif New Formulation
    Medical condition: IFNβ-naïve patients fulfilling Poser or McDonald criteria for CDMS or MS and in whom a decision has been made to initiate treatment with RNF (Rebif New Formulation).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004165-41 Sponsor Protocol Number: STH16542 Start Date*: 2013-11-04
    Sponsor Name:Northwestern University
    Full Title: Hematopoietic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study
    Medical condition: Inflammatory Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000411-91 Sponsor Protocol Number: NKZellen-Version1.0 Start Date*: 2013-02-13
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial
    Medical condition: relapsing-remitting multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000985-36 Sponsor Protocol Number: EMCAM-2011-001 Start Date*: 2013-02-22
    Sponsor Name:JOSE MANUEL GARCIA DOMINGUEZ
    Full Title: Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as "responders" and "not responders" under t...
    Medical condition: Spasticity due to multiple sclerosis identified as "responders" and "not responders" under treatment with Sativex
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10041416 Spasticity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001973-21 Sponsor Protocol Number: GNC-402 Start Date*: 2021-07-09
    Sponsor Name:GeNeuro Innovation SAS
    Full Title: A long-term extension of Study GNC-401 with temelimab in patients with Relapsing forms of Multiple Sclerosis (RMS) under treatment with rituximab
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002648-10 Sponsor Protocol Number: 7109 Start Date*: 2019-04-15
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: TestOsterone TreatmEnt on neuroprotection and Myelin repair in Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001505-24 Sponsor Protocol Number: NOR-MS Start Date*: 2019-07-25
    Sponsor Name:Department of Neurology, Division of Clinical Neuroscience, Oslo University Hospital
    Full Title: Norwegian study of Oral cladribine versus Rituximab in Multiple Sclerosis (NOR-MS). A prospective randomized open-label blinded endpoint (PROBE) multicenter non-inferiority study.
    Medical condition: Relapsing Multiple Sclerosis (RMS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001960-31 Sponsor Protocol Number: 142/2019 Start Date*: 2019-08-27
    Sponsor Name:Turku PET centre
    Full Title: Effect of cladribine treatment on microglial activation in the CNS
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003622-16 Sponsor Protocol Number: T214/2016 Start Date*: 2017-09-19
    Sponsor Name:Turku University Hospital
    Full Title: Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study.
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004791-34 Sponsor Protocol Number: BLOOMS Start Date*: 2022-03-16
    Sponsor Name:VU medical center
    Full Title: Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis: a randomized controlled trial
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000635-13 Sponsor Protocol Number: EMMA Start Date*: 2018-06-08
    Sponsor Name:Universität Leipzig
    Full Title: Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption
    Medical condition: Multiple Sclerosis (MS), acute episode
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003696-12 Sponsor Protocol Number: 109MS301 Start Date*: 2007-03-02
    Sponsor Name:Biogen Idec Ltd.
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) AT (Completed) SE (Prematurely Ended) NL (Completed) GR (Completed) IT (Completed) BG (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 15 23:56:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA